18]. The previous trivalent 2008-
seasonal influenza vaccination has demonstrated moderate protection against laboratory-confirmed pandemic influenza A (H1N1) 2009 associated illness [19] . In addition, during the pandemic, dual vaccination with both H1N1 and seasonal vaccines reduced mortality and hospitalization rates in the institutionalized elderly [20] , and dual vaccination of influenza and pneumococcus reduced mortality among nursing home older adults infected with the pandemic influenza A (H1N1) 2009 virus [21] . However, the available information remains controversial and scarce, and more studies are therefore needed to corroborate these findings in other settings and with different populations.
The aims of the present study were to determine vaccination rates against influenza or S. pneumoniae in a large cohort of hospitalized adults with confirmed influenza A(H1N1)pdm09 infection, and to identify differences in clinical features, frequency of bacterial coinfection, and outcomes between vaccinated and nonvaccinated patients.
Methods

Setting, patients, and study design
This is an observational prospective cohort study conducted at 14 teaching hospitals belonging to the Spanish Network for Research in Infectious Diseases (REIPI). All adult patients (>18 years old) hospitalized with confirmed influenza A(H1N1)pdm09 infection during the pandemic period (April to November 2009) and those hospitalized with pneumonia during the first post-pandemic influenza period (December 2010 to March 2011) were prospectively recruited and followed up.
A confirmed case was defined as a person with an influenza-like illness with confirmed laboratory influenza A(H1N1)pdm09 virus infection documented by real-time polymerase chain reaction (RT-PCR) or viral culture. Influenza A(H1N1)pdm09 virus testing was performed in each institution.
The study was approved by the Ethics Committee of the coordinating center, the Hospital Universitari de Bellvitge, and written informed consent was obtained from patients.
Clinical assessment and follow-up
Patients were seen during their hospital stay by one or more of the researchers in each participating hospital, who recorded clinical data in a standardized, computerassisted protocol. Data were collected on demographic characteristics, pneumococcal and influenza vaccination, comorbidities, clinical signs and symptoms, biochemical analysis, chest X-ray findings, concomitant and/or secondary bacterial pneumonia or infection, antiviral and antibiotic treatment, time to clinical stability, and outcomes, including mortality during hospitalization.
Completed protocols were sent to the coordinating center and all the data were revised by two senior investigators prior to the final validation.
Definitions
Patients were considered to be pneumococcal-vaccinated if 23-valent polysaccharide pneumococcal vaccine had been administered in the five years before admission, and influenza-vaccinated if seasonal influenza vaccine had been administered during the year prior to admission. Vaccination status was determined through interviews with patients or their relatives, as well as from reviews of hospital and personal health records (vaccination card). Pneumonia was defined as the presence of a new infiltrate on a chest radiograph.
Bacterial coinfection was considered to be present in patients who showed positive bacterial blood or respiratory cultures or positive urinary antigen tests for S. pneumoniae or Legionella pneumophila serogroup 1. The study of pathogens in sputum, pleural effusion, bronchoalveolar lavage, and blood was performed by standard microbiologic procedures. Standard serologic methods were used to determine antibodies against atypical agents.
The Pneumonia Severity Index (PSI) [22] and CURB-65 [23] were calculated in each pneumonia episode. Complications were defined as any untoward circumstances occurring during hospitalization. Time to clinical stability was evaluated as described elsewhere [24] . Overall mortality was defined as death from any cause during hospitalization.
The hospital admission criteria, microbiologic studies, intensive care unit (ICU) admission criteria, and treatment decisions were not standardized and were the responsibility of the attending physician.
Statistical analysis
The results were analyzed using a commercially available statistical software package (SPSS, version 15.0; SPSS Inc., Chicago, Illinois). Descriptive statistics were obtained for all study variables, with all proportions being calculated as percentages of the patients with available data.
We compared the clinical characteristics and outcomes between patients who were vaccinated and those who were not vaccinated against influenza and/or S. pneumoniae. The same analysis was performed in patients with vaccine indication according to guidelines, and in those with pneumonia. Significant differences between groups were assessed by means of the chi-square test or Fisher's exact test for categorical variables, as appropriate. Either the Student's t test or the Mann-Whitney test was applied for continuous variables. For outcome variables we also calculated the corresponding odds ratio with 95% confidence interval.
Logistic regression multivariate models were developed for each of the following outcomes: bacterial coinfection, ICU admission, and overall mortality. These multivariate analyses were performed for the whole population and for patients with vaccine indications according to established guidelines. Variables included in the models were influenza or pneumococcal vaccination and all those variables shown to be statistically related with the corresponding outcome variable in the bivariate analysis.
Statistical significance was set at α = 0.05. All reported P values are 2-tailed.
Results
General characteristics of the study population and vaccination rates
A total of 699 adults with influenza A(H1N1)pdm09 infection required hospitalization during the study periods, 585 in the pandemic period and 114 in the first postpandemic period. Of these, 350 (50.1%) had a respiratory tract infection without radiological consolidation and 349 (49.9%) were diagnosed with pneumonia. Demographic characteristics and comorbid conditions for the whole population are summarized in Table 1 .
The vaccination rate was 14% for influenza (77 of 547 with available information on vaccination status) and 5.4% for pneumococcus (32 of 587 with available information). There were no demographic or clinical differences between patients whose vaccination status was known and those in whom it was not established. According to guidelines, 464 (66.4%) of the 699 patients met at least one criterion for administration of influenza and/or pneumococcal vaccines. Sixty (8.5%) patients had a microbiologically documented bacterial co-infection (Table 2 ). S. pneumoniae was documented as the causative pathogen in 41 (5.8%) patients (6 cases had positive sputum culture, 5 bacteremia, and 31 positive urinary antigen test).
At least one complication developed in 137 (12.5%) patients, and it was mainly of a respiratory nature (71 needed invasive ventilation, 50 noninvasive ventilation, 53 showed respiratory distress, 35 pleural effusion, and 3 empyema). Thirty-five (5%) cases presented with septic shock at admission, 119 (17%) patients required ICU admission, and 38 (5.4%) died during hospitalization.
Comparison of clinical and prognostic features between patients who were vaccinated versus not vaccinated against influenza
Among 547 patients with a known influenza vaccination status, 77 had received influenza vaccine. Immunized patients were older, more often male, and were more likely to have chronic comorbid conditions (Table 3 ). Figure 1 displays the main differences in comorbidity rates between vaccinated and non-vaccinated patients.
The main clinical features, complications, and prognostic variables for these groups are summarized in Table 3 . When the analysis was restricted to those patients with influenza vaccine indication according to guidelines, immunized patients were older (52.3 vs. 40.6 years, p<0.001) and had a longer hospital stay (mean 9.1 vs. 6.8 days, p=0.03), but there were no significant differences between the two groups in terms of clinical manifestations, complications or death.
The analysis of patients with pneumonia showed that influenza-immunized patients were older and more often presented comorbidities ( 
Comparison of clinical and prognostic features between patients who were vaccinated versus not vaccinated against S. pneumoniae.
Among 587 patients with a known pneumococcal vaccine status, 32 had been vaccinated. The majority of them were men and they were older and more likely to have chronic comorbid conditions ( Figure 1 ). They also had a shorter time between symptom onset and hospital admission (2.7 vs. 3.7 days, p=0.04), as well as higher lymphocyte counts, PaCO2, and serum bicarbonate. No other differences in clinical manifestations or laboratory values were observed (Table 5 ). One (3.1%) vaccinated patient had a microbiologically confirmed bacterial coinfection (sputum culture positive for Pseudomonas aeruginosa), compared with 45 (8.1%) bacterial coinfections in non-vaccinated patients (68.8% were due to S. pneumoniae). Although vaccinated patients more often required noninvasive ventilation, no other differences were observed in terms of complications or mortality rates between the two groups (Table 5 ).
In the sub-analysis of the 294 patients with pneumonia, 16 (5.4%) had received pneumococcal vaccine, all of them with vaccine indication according to guidelines. As previously observed those immunized were mainly male, older, and more likely to present chronic comorbid conditions. They also had lower baseline oxygen saturation and higher levels of PaCO 2 and serum bicarbonate. Pneumonia episodes were more severe in vaccinated patients, as evidenced by PSI (93.6 vs. 62.5 points, p=0.001) and CURB-65 (1.4 vs. 0.6 points, p<0.001) scores. Finally, noninvasive ventilation was more frequently required by these patients, but no differences were observed for the other outcome variables (Table 5) .
Immunized subjects with pneumonia did not have any microbiologically documented pneumococcal infection or bacteremia, compared, respectively, with 28 (10%) and 4 (1.4%) of non-immunized patients (p>0.05 in each case).
Clinical and prognostic differences between patients vaccinated versus not vaccinated with both vaccines (influenza and S. pneumoniae)
All of the 28 patients who received both vaccines had vaccine indications according to guidelines. As in the previous analysis, vaccinated subjects were mainly men and were older than non-vaccinated patients, and they were also more likely to have chronic comorbid conditions. They also presented lower baseline oxygen saturation and an increased need for noninvasive ventilation. In cases with a pneumonia diagnosis, PSI and CURB-65 scores were also higher for immunized patients (data not shown).
None of the patients who received both vaccines had a pneumococcal infection or bacteremia, compared with 6 (2 with bacteremia) of the 238 (2.5%) who were not vaccinated. 
Multivariate logistic regression analysis
Discussion
In this large cohort study of hospitalized patients with confirmed pandemic influenza A(H1N1)pdm09 infection, we observed low vaccination rates for both seasonal influenza (14%) and S. pneumoniae (5.4%), even in patients who had vaccine indications according to guidelines. In addition, despite conducting whole population and subgroup multivariate analyses, we found that seasonal influenza and pneumococcal vaccines had no beneficial effect in terms of reducing ICU admission or overall mortality. However, patients who had received vaccine (influenza and/or pneumococcal) tended to have fewer bacterial co-infections.
A significant gap between vaccination awareness and actual vaccination rates has been described for both vaccines in different settings [15, 16, 25] . In our study, patients immunized against influenza were mainly men and older; these data are not surprising since a gender effect for vaccine reception has been previously reported [26] , and compliance with influenza vaccination among those under 65 years with comorbidities has varied over time, with low coverage rates of approximately 30% [15, 27] . In our patients the chronic conditions most often related with seasonal influenza vaccine were COPD, heart disease, complicated diabetes mellitus, chronic kidney disease, HIV infection, connective tissue disease, and solid organ transplant.
Especially noteworthy is the low vaccination rate observed among pregnant women in our cohort, of whom only 2.7% had been immunized. Although pregnancy was identified as a risk factor for complications during the pandemic influenza A (H1N1) 2009, the low rate of seasonal influenza vaccination during the 2008-2009 vaccine campaign, before the first cases of pandemic influenza (H1N1) 2009 were diagnosed in the spring of 2009, is substantially below target levels [28] . The subjective perceived low risk of infection and concerns about vaccine safety could be responsible for poorer vaccination rates in the first postpandemic season, both in pregnant women and in other risk groups. An epidemiological study of vaccination against 2009 season influenza in Spain concluded that the coverage finally achieved among people with an indication due to a chronic health condition in the H1N1 campaign was much lower than expected [29] .
Another noteworthy finding is the fact that immunized patients presented more complications, mainly shock, ICU admissions, need for noninvasive ventilation, and mortality. This is probably due to a selection bias, since the baseline risk of this group was increased by their being older and having more chronic conditions. Although the efficacy and effectiveness of influenza vaccination have been clearly demonstrated [30, 31] , a Cochrane review concluded that while influenza vaccination in patients with COPD significantly reduced acute exacerbations with an effectiveness over 60%, there was no evidence of an effect on hospitalization or mortality rates [32] . In our study, neither influenza nor pneumococcal vaccination was related in the multivariate analyses with a lower rate of ICU admission, mortality, or bacterial co-infection.
As already mentioned, previous seasonal influenza vaccination, when the circulating influenza strain was not matched by the trivalent seasonal influenza vaccine, was related to better prognosis in patients infected with influenza A(H1N1) pdm09 [21] . Moreover, prior vaccination with seasonal influenza vaccines in 2004-2008 was independently associated with protection in a recent study [19] . However, the population in that study comprised active-duty military service members, a high proportion of whom were younger than 40 years (94.3%), and with vaccination rates over 80%. Other study of institutionalized elderly patients in Hong Kong [20] found that dual vaccination of pandemic influenza A (H1N1) 2009 virus and seasonal influenza reduced allcause hospitalization, as well as hospitalization for fever on admission and for pneumonia, compared with seasonal vaccination alone. An additive effect of seasonal influenza and pneumococcal vaccination has also been described on all-cause mortality and mortality from pneumonia or from vascular causes [21] . However, in these two studies the majority of the population were women (>60%), no laboratory-confirmed influenza infection was required, and the etiology of pneumonia (viral or bacterial) was not specified. Furthermore, the results cannot be extrapolated to all elderly persons not living in nursing homes.
The analysis of both the whole population and of patients with a vaccine indication revealed a longer hospital stay and greater use of antibiotics among immunized patients. These data do not support the idea that the influenza vaccine can lead to savings in terms of hospitalization costs. However, it should be noted that although there is widespread evidence of the cost-effectiveness of influenza vaccination [33, 34] this need not necessarily be the case in a particular high-risk population, such as ours, or in the context of an influenza pandemic.
Similar reasoning can be applied to explain the differences observed between patients vaccinated and those not vaccinated against pneumococcus. Once again, immunized patients tended to be older men with comorbidities, and they had more severe episodes. A high proportion of them also needed noninvasive ventilation. There were no differences with respect to the other outcome variables or mortality, although this may simply be due to the low number of immunized subjects. In our study only 28 patients had received both vaccines, even though there is some evidence that the benefits of influenza and pneumococcal vaccination may be additive in preventing hospitalization and death in high-risk groups, and even cost-effective [35] [36] [37] .
It should be emphasized that bacterial infections tended to be less frequent among vaccinated patients in the present study. Only two pneumococcal infections were microbiologically documented among those who received influenza vaccine, and neither of them was invasive. Moreover, no pneumococcal infection was diagnosed among subjects who were immunized for S. pneumoniae. Although clinical studies have produced conflicting results regarding the utility of pneumococcal vaccination in some populations [38] [39] [40] our data may support vaccination for high-risk patients.
Our study does have a number of limitations. Firstly, we only included hospitalized patients, who represent only a small proportion of those with influenza A(H1N1) pdm09 infection and who are likely to have a more severe clinical presentation and worse prognosis. A second limitation concerns the fact that we reviewed the effect of seasonal influenza vaccine on the clinical presentation and outcome of influenza A(H1N1) pdm09 infection in two different periods, the pandemic one and the first post-pandemic season, considering further that in the second period the seasonal influenza vaccine contained the H1N1 strain. However, in this second period we only had data for pneumonia episodes. It is also acknowledged that most of the vaccination data were self-reported, although there is evidence that self-reports, at least regarding influenza vaccination, are highly sensitive and evince a high level of agreement [17] . The strengths of this work include the fact that it was a multicenter study involving a large cohort of patients from 14 hospitals located in seven cities from across Spain. It is therefore reasonable to assume that our data offer a fair reflection of immunization practices, and their influence on clinical outcomes in different types of patients who were admitted with influenza A(H1N1) pdm09 infection to major centers during that period. However, it should be noted that for some outcome variables the small number of events meant that the analysis had insufficient statistical power to identify significant differences.
Conclusion
Vaccination rates against influenza and pneumococcus were low in hospitalized patients with influenza A(H1N1) pdm09 infection. In addition, no significant differences in outcomes between vaccinated and non-vaccinated patients were documented. However, vaccinated patients tended to have fewer S. pneumoniae bacterial co-infections. 
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